

Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026

In accordance with the Nomination Committee Charter adopted at the Annual General Meeting 2025, the members who, together with the Chair of the Board, constitute the Nomination Committee in preparation of the Annual General Meeting 2026 have been elected.

The Nomination Committee consists of:
Niels Jacobsen, appointed by William Demant Invest A/S
Patrik Tigerschiöld, appointed by Bure Equity AB
Patricia Hedelius, appointed by AMF Fonder & Pension
Jón Sigurdsson, Chairman of the Board

The Annual General Meeting of Vitrolife AB will be held in Gothenburg on 6 May 2026.

Shareholders who wish to submit proposals to the Nomination Committee may contact the Chair of the Board of Vitrolife AB on e-mail: investors@vitrolife.com.

Gothenburg, October 29, 2025
VITROLIFE AB (publ)

Contact:

Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.